← All trials
NCT05702983
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jan 31, 2023
- Primary completion
- Apr 11, 2023
- Completion date
- Apr 24, 2023
- First posted
- Jan 27, 2023
- Last posted
- May 26, 2023
- Enrollment
- 20
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Staidson (Beijing) Biopharmaceuticals Co., LtdLead sponsor
- Altasciences Company Inc.Overall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.